EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer

Philip D. Dunne, Sonali Dasgupta, Jaine K. Blayney, Darragh G. McArt, Keara L. Redmond, Jessica Anne Weir, Conor A. Bradley, Takehiko Sasazuki, Senji Shirasawa, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Manuel Salto-Tellez, Richard H. Wilson, Patrick G. Johnston, Sandra Van Schaeybroeck

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose: EphA2, a member of the Eph receptor tyrosine kinases family, is an important regulator of tumor initiation, neovascularization, and metastasis in a wide range of epithelial and mesenchymal cancers; however, its role in colorectal cancer recurrence and progression is unclear. Experimental Design: EphA2 expression was determined by immunohistochemistry in stage II/III colorectal tumors (N = 338), and findings correlated with clinical outcome. The correlation between EphA2 expression and stem cell markers CD44 and Lgr5 was examined. The role of EphA2 in migration/invasion was assessed using a panel of KRAS wild-type (WT) and mutant (MT) parental and invasive colorectal cancer cell line models. Results: Colorectal tumors displayed significantly higher expression levels of EphA2 compared with matched normal tissue, which positively correlated with high CD44 and Lgr5 expression levels. Moreover, high EphA2 mRNA and protein expression were found to be associated with poor overall survival in stage II/III colorectal cancer tissues, in both univariate and multivariate analyses. Preclinically, we found that EphA2 was highly expressed in KRASMT colorectal cancer cells and that EphA2 levels are regulated by the KRAS-driven MAPK and RalGDS-RalA pathways. Moreover, EphA2 levels were elevated in several invasive daughter cell lines, and downregulation of EphA2 using RNAi or recombinant EFNA1 suppressed migration and invasion of KRASMT colorectal cancer cells. Conclusions: These data show that EpHA2 is a poor prognostic marker in stage II/III colorectal cancer, which may be due to its ability to promote cell migration and invasion, providing support for the further investigation of EphA2 as a novel prognostic biomarker and therapeutic target.

Original languageEnglish
Pages (from-to)230-242
Number of pages13
JournalClinical Cancer Research
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Colorectal Neoplasms
EphA2 Receptor
Eph Family Receptors
Cell Line
RNA Interference
Cell Movement
Neoplasms
Research Design
Stem Cells
Down-Regulation
Multivariate Analysis
Biomarkers
Immunohistochemistry
Neoplasm Metastasis
Recurrence
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Dunne, P. D., Dasgupta, S., Blayney, J. K., McArt, D. G., Redmond, K. L., Weir, J. A., ... Van Schaeybroeck, S. (2016). EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clinical Cancer Research, 22(1), 230-242. https://doi.org/10.1158/1078-0432.CCR-15-0603

EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. / Dunne, Philip D.; Dasgupta, Sonali; Blayney, Jaine K.; McArt, Darragh G.; Redmond, Keara L.; Weir, Jessica Anne; Bradley, Conor A.; Sasazuki, Takehiko; Shirasawa, Senji; Wang, Tingting; Srivastava, Supriya; Ong, Chee Wee; Arthur, Ken; Salto-Tellez, Manuel; Wilson, Richard H.; Johnston, Patrick G.; Van Schaeybroeck, Sandra.

In: Clinical Cancer Research, Vol. 22, No. 1, 01.01.2016, p. 230-242.

Research output: Contribution to journalArticle

Dunne, PD, Dasgupta, S, Blayney, JK, McArt, DG, Redmond, KL, Weir, JA, Bradley, CA, Sasazuki, T, Shirasawa, S, Wang, T, Srivastava, S, Ong, CW, Arthur, K, Salto-Tellez, M, Wilson, RH, Johnston, PG & Van Schaeybroeck, S 2016, 'EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer', Clinical Cancer Research, vol. 22, no. 1, pp. 230-242. https://doi.org/10.1158/1078-0432.CCR-15-0603
Dunne, Philip D. ; Dasgupta, Sonali ; Blayney, Jaine K. ; McArt, Darragh G. ; Redmond, Keara L. ; Weir, Jessica Anne ; Bradley, Conor A. ; Sasazuki, Takehiko ; Shirasawa, Senji ; Wang, Tingting ; Srivastava, Supriya ; Ong, Chee Wee ; Arthur, Ken ; Salto-Tellez, Manuel ; Wilson, Richard H. ; Johnston, Patrick G. ; Van Schaeybroeck, Sandra. / EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 1. pp. 230-242.
@article{3431ddbf5ef44a7ebab22a46eff34aab,
title = "EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer",
abstract = "Purpose: EphA2, a member of the Eph receptor tyrosine kinases family, is an important regulator of tumor initiation, neovascularization, and metastasis in a wide range of epithelial and mesenchymal cancers; however, its role in colorectal cancer recurrence and progression is unclear. Experimental Design: EphA2 expression was determined by immunohistochemistry in stage II/III colorectal tumors (N = 338), and findings correlated with clinical outcome. The correlation between EphA2 expression and stem cell markers CD44 and Lgr5 was examined. The role of EphA2 in migration/invasion was assessed using a panel of KRAS wild-type (WT) and mutant (MT) parental and invasive colorectal cancer cell line models. Results: Colorectal tumors displayed significantly higher expression levels of EphA2 compared with matched normal tissue, which positively correlated with high CD44 and Lgr5 expression levels. Moreover, high EphA2 mRNA and protein expression were found to be associated with poor overall survival in stage II/III colorectal cancer tissues, in both univariate and multivariate analyses. Preclinically, we found that EphA2 was highly expressed in KRASMT colorectal cancer cells and that EphA2 levels are regulated by the KRAS-driven MAPK and RalGDS-RalA pathways. Moreover, EphA2 levels were elevated in several invasive daughter cell lines, and downregulation of EphA2 using RNAi or recombinant EFNA1 suppressed migration and invasion of KRASMT colorectal cancer cells. Conclusions: These data show that EpHA2 is a poor prognostic marker in stage II/III colorectal cancer, which may be due to its ability to promote cell migration and invasion, providing support for the further investigation of EphA2 as a novel prognostic biomarker and therapeutic target.",
author = "Dunne, {Philip D.} and Sonali Dasgupta and Blayney, {Jaine K.} and McArt, {Darragh G.} and Redmond, {Keara L.} and Weir, {Jessica Anne} and Bradley, {Conor A.} and Takehiko Sasazuki and Senji Shirasawa and Tingting Wang and Supriya Srivastava and Ong, {Chee Wee} and Ken Arthur and Manuel Salto-Tellez and Wilson, {Richard H.} and Johnston, {Patrick G.} and {Van Schaeybroeck}, Sandra",
year = "2016",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-15-0603",
language = "English",
volume = "22",
pages = "230--242",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer

AU - Dunne, Philip D.

AU - Dasgupta, Sonali

AU - Blayney, Jaine K.

AU - McArt, Darragh G.

AU - Redmond, Keara L.

AU - Weir, Jessica Anne

AU - Bradley, Conor A.

AU - Sasazuki, Takehiko

AU - Shirasawa, Senji

AU - Wang, Tingting

AU - Srivastava, Supriya

AU - Ong, Chee Wee

AU - Arthur, Ken

AU - Salto-Tellez, Manuel

AU - Wilson, Richard H.

AU - Johnston, Patrick G.

AU - Van Schaeybroeck, Sandra

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose: EphA2, a member of the Eph receptor tyrosine kinases family, is an important regulator of tumor initiation, neovascularization, and metastasis in a wide range of epithelial and mesenchymal cancers; however, its role in colorectal cancer recurrence and progression is unclear. Experimental Design: EphA2 expression was determined by immunohistochemistry in stage II/III colorectal tumors (N = 338), and findings correlated with clinical outcome. The correlation between EphA2 expression and stem cell markers CD44 and Lgr5 was examined. The role of EphA2 in migration/invasion was assessed using a panel of KRAS wild-type (WT) and mutant (MT) parental and invasive colorectal cancer cell line models. Results: Colorectal tumors displayed significantly higher expression levels of EphA2 compared with matched normal tissue, which positively correlated with high CD44 and Lgr5 expression levels. Moreover, high EphA2 mRNA and protein expression were found to be associated with poor overall survival in stage II/III colorectal cancer tissues, in both univariate and multivariate analyses. Preclinically, we found that EphA2 was highly expressed in KRASMT colorectal cancer cells and that EphA2 levels are regulated by the KRAS-driven MAPK and RalGDS-RalA pathways. Moreover, EphA2 levels were elevated in several invasive daughter cell lines, and downregulation of EphA2 using RNAi or recombinant EFNA1 suppressed migration and invasion of KRASMT colorectal cancer cells. Conclusions: These data show that EpHA2 is a poor prognostic marker in stage II/III colorectal cancer, which may be due to its ability to promote cell migration and invasion, providing support for the further investigation of EphA2 as a novel prognostic biomarker and therapeutic target.

AB - Purpose: EphA2, a member of the Eph receptor tyrosine kinases family, is an important regulator of tumor initiation, neovascularization, and metastasis in a wide range of epithelial and mesenchymal cancers; however, its role in colorectal cancer recurrence and progression is unclear. Experimental Design: EphA2 expression was determined by immunohistochemistry in stage II/III colorectal tumors (N = 338), and findings correlated with clinical outcome. The correlation between EphA2 expression and stem cell markers CD44 and Lgr5 was examined. The role of EphA2 in migration/invasion was assessed using a panel of KRAS wild-type (WT) and mutant (MT) parental and invasive colorectal cancer cell line models. Results: Colorectal tumors displayed significantly higher expression levels of EphA2 compared with matched normal tissue, which positively correlated with high CD44 and Lgr5 expression levels. Moreover, high EphA2 mRNA and protein expression were found to be associated with poor overall survival in stage II/III colorectal cancer tissues, in both univariate and multivariate analyses. Preclinically, we found that EphA2 was highly expressed in KRASMT colorectal cancer cells and that EphA2 levels are regulated by the KRAS-driven MAPK and RalGDS-RalA pathways. Moreover, EphA2 levels were elevated in several invasive daughter cell lines, and downregulation of EphA2 using RNAi or recombinant EFNA1 suppressed migration and invasion of KRASMT colorectal cancer cells. Conclusions: These data show that EpHA2 is a poor prognostic marker in stage II/III colorectal cancer, which may be due to its ability to promote cell migration and invasion, providing support for the further investigation of EphA2 as a novel prognostic biomarker and therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=84954526582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954526582&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-0603

DO - 10.1158/1078-0432.CCR-15-0603

M3 - Article

C2 - 26283684

AN - SCOPUS:84954526582

VL - 22

SP - 230

EP - 242

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -